SAN DIEGO, Calif.--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates two years of progress in pioneering a novel non-profit approach to providing personalized experimental antisense ...
To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 160 applications for treatment with more than 80 nano-rare patients approved. n-Lorem was ...
SAN DIEGO and GENEVA, Jan. 12, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...
Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis ...
n-Lorem, a nonprofit foundation, announced today that the 50 th nano-rare patient has been treated with a personalized, experimental antisense oligonucleotide (ASO) medicine discovered, developed and ...
Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine ...
Foundation’s collaboration with premier rare disease company strengthens efforts to reach more patients in need n-Lorem Foundation is the first and only foundation with a mission to provide ...
n-Lorem’s Patient Empowerment Program Approaches One Year Mark With More Than 5000 Episode Downloads
New community Q&A format provides community input and discussion with founder and host Stan Crooke SAN DIEGO--(BUSINESS WIRE)--#ASO--n-Lorem, a nonprofit foundation, celebrates a year of connecting ...
CARLSBAD, Calif., April 14, 2020 /PRNewswire/ -- The n-Lorem Foundation announced today it has received a pledge of $500,000 from Paul and Andrea Compton in support of the n-Lorem Foundation's efforts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results